ARTICLE | Product Development
Not done yet. The COVID R&D Alliance has plenty on its plate for 2021
Takeda’s Andy Plump and Theravance’s Brett Haumann discuss the consortium’s priorities, and what lessons carry forward for 2021 and beyond
January 1, 2021 1:36 AM UTC
With little fuss or fanfare, the COVID R&D Alliance was created early in the pandemic by the biopharma industry’s biggest players to solve one of the world’s most devastating problems in a century. Now, the looming question for this and the other COVID consortia is where do they go from here, as success on the vaccine front offers hope for an end to the emergency.
BioCentury sat down, virtually, with Andrew Plump and Brett Haumann, two members of the 22-strong COVID R&D Alliance, to discuss how the group views its mission in the coming year. Plump is President of R&D at Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) and Haumann is CMO at Theravance Biopharma Inc. (NASDAQ:TBPH)...